Publications by authors named "Marta Pestrin"

Claim this Profile
E
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer.
Riccardo Scandino, Agostina Nardone, Nicola Casiraghi, Francesca Galardi, Mattia Genovese, Marta Pestrin

NPJ Breast Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples.
Dario Romagnoli, Agostina Nardone, Francesca Galardi, Marta Paoli, Francesca De Luca, Marta Pestrin

Brief Bioinform· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Caterina Fontanella, Carlo Alberto Giorgi, Stefania Russo, Silvia Angelini, Linda Nicolardi, Marta Pestrin

Crit Rev Oncol Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.
Giuseppina Sanna, Marta Pestrin, Erica Moretti, Chiara Biagioni, Irene De Santo

Clin Breast Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution.
Giacomo Barchiesi, Amelia McCartney, Chiara Biagioni, Olimpia Siclari, Lorenzo Rossi, Marta Pestrin

Breast J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
Amelia McCartney, Chiara Biagioni, Gaia Schiavon, Mattias Bergqvist, Karin Mattsson, Marta Pestrin

Eur J Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Marta Pestrin

Breast Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Erica Moretti, Marta Pestrin

Anticancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of abemaciclib in treatment of advanced breast cancer.
Amelia McCartney, Erica Moretti, Giuseppina Sanna, Marta Pestrin, Emanuela Risi

Ther Adv Med Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.
Martina Bonechi, Francesca Galardi, Chiara Biagioni, Francesca De Luca, Mattias Bergqvist, Marta Pestrin

Oncotarget· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
Francesca De Luca, Giada Rotunno, Francesca Salvianti, Francesca Galardi, Marta Pestrin

Oncotarget· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using CTCs for pharmacogenomic analysis.
Christopher D Hart, Francesca Galardi, Marta Pestrin, Francesca De Luca, Emanuela Risi

Pharmacol Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy: which patient? What regimen?
Natalie Turner, Laura Biganzoli, Luca Malorni, Ilenia Migliaccio, Erica Moretti, Marta Pestrin

Am Soc Clin Oncol Educ Book· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing.
Francesca Salvianti, Giada Rotunno, Francesca Galardi, Francesca De Luca, Marta Pestrin

Biomol Detect Quantif· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Marta Pestrin, Francesca Salvianti, Francesca Galardi, Francesca De Luca, Natalie Turner

Mol Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International study on inter-reader variability for circulating tumor cells in breast cancer.
Michail Ignatiadis, Sabine Riethdorf, François-Clement Bidard, Isabelle Vaucher, Mustapha Khazour, Marta Pestrin

Breast Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?
Natalie Turner, Marta Pestrin, Francesca Galardi, Francesca De Luca, Luca Malorni

Cancers (Basel)· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
Justin Stebbing, Rachel Payne, Justine Reise, Adam E Frampton, Miranda Avery, Marta Pestrin

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The continued evidence from overviews: what is the clinical utility?
Natalie Turner, Laura Biganzoli, Luca Malorni, Ilenia Migliaccio, Erica Moretti, Marta Pestrin

Breast· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M Minisini, Giovanna Masci

Breast Cancer Res Treat· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-positive circulating tumor cells in breast cancer.
Michail Ignatiadis, Françoise Rothé, Carole Chaboteaux, Virginie Durbecq, Ghizlane Rouas, Marta Pestrin

PLoS One· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.
Catherine Oakman, Marta Pestrin, Silvia Bessi, Francesca Galardi, Angelo Di Leo

Cancers (Basel)· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.
Catherine Oakman, Marta Pestrin, Elena Zafarana, Egidia Cantisani, Angelo Di Leo

Cancer Manag Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
Marta Pestrin, Silvia Bessi, Francesca Galardi, Mara Truglia, Annibale Biggeri

Breast Cancer Res Treat· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
Catherine Oakman, Marta Pestrin, Egidia Cantisani, Sara Licitra, Matilde DeStefanis

Breast· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis